NEW YORK (TheStreet) -- BioMarin Pharmaceutical (BMRN) - Get Report shares are up 11.77% to $129.15 in trading on Friday after analysts at Deutsche Bank (DB) - Get Report said that the company may be the latest biotech target.
Fellow biotech company Shire (SHPG) - Get Report is close to acquiring the company, according to analyst sources. Deutsche Bank analyst Robyn Karnauskas believes that the company could rise to trade close to $300 over the next year.
Ben Harrington of the blog Betaville reported on the merger talks last night saying that Morgan Stanley (MS) - Get Report and Lazard (LAZ) - Get Report are advising Shire on a deal that could be worth $65 billion, according to analyst sources.
TheStreet has further coverage of the possible merger here.
TheStreet Ratings team rates BIOMARIN PHARMACEUTICAL INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:
"We rate BIOMARIN PHARMACEUTICAL INC (BMRN) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: BMRN Ratings Report